Gastroenterology

Francisco A. Sylvester, MD, UNC School of Medicine talked about the different ways in which the care of pediatric IBD differs from adult IBD.

Peter Higgins, MD, PhD, University of Michigan Health System, talked about how patients these days are often answering their own nutritional questions on the "Wild Wild West" of the Internet, so it's up to the experts to provide thorough answers to assuage their concerns.

At the 2015 Advances in Inflammatory Bowel Diseases (AIBD) meeting in Orlando, Florida, Peter Higgins, MD, PhD, the University of Michigan Health System shared his insight about the importance and value of careful nutritional guidance for IBD patients.

It’s been suggested that probiotics can help prevent relapses in ulcerative colitis, but a new analysis presented in a poster session at the 2015 Advances in Inflammatory Bowel Diseases conference (AIBD 2015) in Orlando, Florida argues that that’s not the case.

Measures in place to limit systemic steroid use for patients with inflammatory bowel disease are not as effective as they need to be. They should be replaced by a two-part model to examine drug utilization patterns that would separately consider factors associated with initiation and duration of therapy.

Hospitalization and mortality is more likely in elderly patients with inflammatory bowel disease (IBD) when compared to their younger counterparts. With 5-aminosalicylates (5-ASA) and corticosteroids becoming more popular in this age group, it’s not clear how they affect patients in the long run.

Eva Szigethy, MD, PhD, University of Pittsburgh discussed at the 2015 Advances in Inflammatory Bowel Diseases (AIBD) how to continue the conversation and implement methods to treat the burgeoning concern of opioid dependence among pediatric IBD patients.

Study results show that patients with ulcerative colitis who undergo hematopoietic stem cell transplantation (HSCT) had higher rates of opportunistic infections and inpatient mortality compared to transplant patients who did not have UC.

Miguel Regueiro, MD, University of Pittsburgh Medical Center, highlighted the hot topics in IBD at the 2015 Advances in Inflammatory Bowel Diseases.

Researchers examined the possible connection between vitamin D levels and IBD in a cohort of African American patients with IBD and a control group of those patients’ African American healthy spouses and friends.

Fatigue is two to three times more likely to appear in patients with inflammatory bowel disease (IBD) than in healthy controls. Researchers from Østfold University College in Norway found that the common symptom can lead to additional interferences.

Russell Cohen, MD, director of the Inflammatory Bowel Diseases Center at The University of Chicago Medicine continued to discuss the relevance of healthcare economics specific to IBD at the 2015 Advances in Inflammatory Bowel Diseases.

Russell Cohen, MD, director of the Inflammatory Bowel Diseases Center at The University of Chicago Medicine, discussed the progress made not only in the clinical care of IBD, but also in the basic science group and translational core at the 2015 Advances in Inflammatory Bowel Diseases meeting in Orlando, FL.

Nonalcoholic fatty liver disease (NAFLD) is now the most common hepatic pathology in developed nations. Public health officials are worried, as NAFLD increases the likelihood of diabetes, cardiovascular disease and chronic kidney disease.

Treating hepatitis C sooner rather than later -- even at the early stages of liver fibrosis -- is worth the thousands of dollars it costs to pay for the new, more effective drugs, according to researchers who developed a model to assess historical treatment data.

Part of an ongoing series that takes a high-level look at the positions of the leading nominees for President when it comes to political issues potentially impacting physicians, this installment focuses on Donald Trump.

Part of an ongoing series that takes a high-level look at the positions of the leading nominees for President when it comes to political issues potentially impacting physicians, this installment focuses on Jeb Bush.

Treatment for irritable bowel syndrome (IBS) is significantly more expensive when treated in secondary care settings than it is when treated in primary care settings -- without a corresponding increase in treatment effectiveness.

A recent study suggests that high salt intake is closely associated with elevated risks of developing non-alcoholic fatty liver disease (NAFLD).

With the amount of information we are hit with day in and day out, our minds need a way of quickly triaging it. This is what stereotyping does. But let's not confuse stereotyping with prejudice. The latter is negative and the former doesn't have to be.

A US Senate investigation found that drug maker Gilead Sciences sought to maximize profits of its blockbuster hepatitis C drug, without any significant consideration of the thousands of patients who could not afford its pricey pill.

The Patient-Centered Outcomes Research Institute (PCORI) has awarded a $14 million grant to a research team at Montefiore Health System and Albert Einstein College of Medicine to determine how best to treat hepatitis C virus (HCV) among people who have used injectable drugs.

New research shows that ramosetron reduces symptoms of irritable bowel syndrome (IBS) and increases stool consistency and quality of life in women.

Adding potatoes, despite their high carbohydrate content, to one's daily diet can reduce the likelihood of stomach cancer by one third.

The key to determining the level to which inflammatory bowel disease (IBD) patients might become sick is to understand patients' genetic variation.

The risk of developing psoriasis can be attributed to infections, not antibiotic use.

Researchers have revealed the discovery of a new gene that allows bacteria to become resistant to colistin, considered the "last line of defense" to antibiotic resistance.

Researchers have developed a method to screen for hepatitis C using a urine test that is faster and cheaper than traditional blood tests.

In the past patients with alcoholic liver disease may not have been considered viable options for liver transplants. A recent study looked at whether an artificial device could help these patients return to a normal quality of life.

Mobile applications can significantly aid in treatment for gastrointestinal conditions.